William A. Weiss, MD, PhD

William A. Weiss, MD, PhD

Professor, Departments of Neurology, Pediatrics, and Neurological Surgery, UCSF; Co-Leader, Pediatric Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center


Phone: (415) 353-2525 (appts), 502-1694 (office)
Box 0663, UCSF
San Francisco, CA 94143-0663

View on UCSF Profiles

Cancer Center Membership

Program Member » Neurologic Oncology» Pediatric Malignancies


Tufts University, Medford, MA, BS, 1978-1982, Biology
Stanford University, Stanford, CA, MD, PhD, 1982-1989, Medicine/Cancer Biology

Professional Experience

  • 1989-1991
    Children's Hospital, Boston MA, Intern and Resident in Pediatrics
  • 1991-1992
    University of California, San Francisco, Resident in Neurology & Child Neurology
  • 1994-1998
    University of California, San Francisco, Post-Doctoral Fellow (under J. Michael Bishop)
  • 1999-present
    University of California, San Francisco, Asst (1998), Associate (2004), Full Professor(2008), Neurology, Pediatrics, Neurosurgery
  • 2011-2012
    University of California, San Francisco, Director, Child Neurology Division

Honors & Awards

  • 1981
    Phi Beta Kappa
  • 1982
    BS degree awarded with honors (Summa Cum Laude)
  • 1994
    Daland Research Fellow, American Philosophical Society
  • 1996-2001
    Burroughs Wellcome Career Development Award
  • 1997
    UCSF Grumbach Research Award
  • 1997
    Child Neurology Society Young Investigator Award
  • 1999
    UCSF Brook Byers Award in Basic Science
  • 1999-2004
    Steering Committee Member and Nervous System Cancers Committee Chair: NCI sponsored Mouse Models for Human Cancer Consortium
  • 2001-2003
    Sydney Kimmel Scholar Award
  • 2002-2004, 2005
    Brain Tumor Society Scholar
  • 2005
    Integrative Research Award, UCSF Sandler Program in Basic Sciences
  • 2005
    Thrasher Research Fund Award
  • 2005
    Samuel Waxman Cancer Research Foundation Award
  • 2005
    Goldhirsh Foundation Award
  • 2006
    National Brain Tumor Foundation Award
  • 2006
    Burroughs Wellcome Translational Research Award
  • 2008
    Alex Lemonade Stand Foundation Award
  • 2002, 2008
    Accelerate Brain Cancer Cure Award
  • 2008, 2005, 2002
    Brain Tumor Society Award

Selected Publications

  1. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015 Sep 8; 6(26):21993-2005.
    View on PubMed
  2. STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma. Cancer Res. 2015 Oct 15; 75(20):4302-11.
    View on PubMed
  3. EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci. 2015 Sep; 18(9):1236-46.
    View on PubMed
  4. Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Front Oncol. 2015; 5:111.
    View on PubMed
  5. Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clin Cancer Res. 2015 Aug 15; 21(16):3750-8.
    View on PubMed
  6. The genetics of splicing in neuroblastoma. Cancer Discov. 2015 Apr; 5(4):380-95.
    View on PubMed
  7. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun. 2014; 2(1):174.
    View on PubMed
  8. Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell. 2015 Jan 12; 27(1):72-84.
    View on PubMed
  9. Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma. Mol Cancer Ther. 2015 Feb; 14(2):419-28.
    View on PubMed
  10. Expression Quantitative Trait Loci and Receptor Pharmacology Implicate Arg1 and the GABA-A Receptor as Therapeutic Targets in Neuroblastoma. Cell Rep. 2014 Nov 6; 9(3):1034-46.
    View on PubMed
  11. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014 Sep 8; 26(3):414-27.
    View on PubMed
  12. When deletions gain functions: commandeering epigenetic mechanisms. Cancer Cell. 2014 Aug 11; 26(2):160-1.
    View on PubMed
  13. An improved monomeric infrared fluorescent protein for neuronal and tumour brain imaging. Nat Commun. 2014; 5:3626.
    View on PubMed
  14. The prenatal origins of cancer. Nat Rev Cancer. 2014 Apr; 14(4):277-89.
    View on PubMed
  15. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014 Mar 20; 32(9):886-96.
    View on PubMed
  16. Alternative splicing in cancer: implications for biology and therapy. Oncogene. 2015 Jan 2; 34(1):1-14.
    View on PubMed
  17. Residual analysis of the water resonance signal in breast lesions imaged with high spectral and spatial resolution (HiSS) MRI: a pilot study. Med Phys. 2014 Jan; 41(1):012303.
    View on PubMed
  18. Glial progenitors as targets for transformation in glioma. Adv Cancer Res. 2014; 121:1-65.
    View on PubMed
  19. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014 Jan 10; 343(6167):189-93.
    View on PubMed
  20. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014 Feb 15; 20(4):912-25.
    View on PubMed

Go to UCSF Profiles, powered by CTSI